Thomas R. Cannell - 18 Feb 2022 Form 4 Insider Report for Sesen Bio, Inc. (CARM)

Role: President and CEO, Director
Signature: /s/ Thomas R. Cannell
Issuer symbol: CARM
Transactions as of: 18 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 23 Feb 2022, 19:36:22 UTC
Next filing: 23 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CARM	Common Stock	Award	$0	+606,800		$0.000000	606,800	18 Feb 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") which shall vest annually in equal amounts over a four-year period following the grant date, so long as the reporting person remains employed by Sesen Bio, Inc.(the "Company"). Each RSU represents a contingent right to receive one share of the Company's common stock. Based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies, the compensation committee of the Company recommended to the Company's board of directors, and the board of directors approved, the grant to the reporting person.

Content

Represents restricted stock units ("RSUs") which shall vest annually in equal amounts over a four-year period following the grant date, so long as the reporting person remains employed by Sesen Bio, Inc.(the "Company"). Each RSU represents a contingent right to receive one share of the Company's common stock. Based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies, the compensation committee of the Company recommended to the Company's board of directors, and the board of directors approved, the grant to the reporting person.